Research ExplorerPublicationsTreatments used for obsessive-compulsive disorder-An interna...

Treatments used for obsessive-compulsive disorder-An international perspective

Standard

Treatments used for obsessive-compulsive disorder-An international perspective. / Brakoulias, Vlasios; Starcevic, Vladan; Albert, Umberto; Arumugham, Shyam Sundar; Bailey, Brenda E; Belloch, Amparo; Borda, Tania; Dell'Osso, Liliana; Elias, Jason A; Falkenstein, Martha J; Ferrao, Ygor A; Fontenelle, Leonardo F; Jelinek, Lena; Kalogeraki, Leto; Kay, Brian; Laurito, Luana D; Lochner, Christine; Maina, Giuseppe; Marazziti, Donatella; Martin, Andrew; Matsunaga, Hisato; Miguel, Euripedes C; Morgado, Pedro; Mourikis, Irakis; Pasquini, Massimo; Perez Rivera, Rodrigo; Potluri, Sriramya; Reddy, Janardhan Y C; Riemann, Brian C; do Rosario, Maria Conceição; Shavitt, Roseli G; Stein, Dan J; Viswasam, Kirupumani; Wang, Zhen; Fineberg, Naomi A.

In: HUM PSYCHOPHARM CLIN, Vol. 34, No. 1, 01.2019, p. e2686.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brakoulias, V, Starcevic, V, Albert, U, Arumugham, SS, Bailey, BE, Belloch, A, Borda, T, Dell'Osso, L, Elias, JA, Falkenstein, MJ, Ferrao, YA, Fontenelle, LF, Jelinek, L, Kalogeraki, L, Kay, B, Laurito, LD, Lochner, C, Maina, G, Marazziti, D, Martin, A, Matsunaga, H, Miguel, EC, Morgado, P, Mourikis, I, Pasquini, M, Perez Rivera, R, Potluri, S, Reddy, JYC, Riemann, BC, do Rosario, MC, Shavitt, RG, Stein, DJ, Viswasam, K, Wang, Z & Fineberg, NA 2019, 'Treatments used for obsessive-compulsive disorder-An international perspective', HUM PSYCHOPHARM CLIN, vol. 34, no. 1, pp. e2686. https://doi.org/10.1002/hup.2686

APA

Brakoulias, V., Starcevic, V., Albert, U., Arumugham, S. S., Bailey, B. E., Belloch, A., Borda, T., Dell'Osso, L., Elias, J. A., Falkenstein, M. J., Ferrao, Y. A., Fontenelle, L. F., Jelinek, L., Kalogeraki, L., Kay, B., Laurito, L. D., Lochner, C., Maina, G., Marazziti, D., ... Fineberg, N. A. (2019). Treatments used for obsessive-compulsive disorder-An international perspective. HUM PSYCHOPHARM CLIN, 34(1), e2686. https://doi.org/10.1002/hup.2686

Vancouver

Brakoulias V, Starcevic V, Albert U, Arumugham SS, Bailey BE, Belloch A et al. Treatments used for obsessive-compulsive disorder-An international perspective. HUM PSYCHOPHARM CLIN. 2019 Jan;34(1):e2686. https://doi.org/10.1002/hup.2686

Bibtex

@article{a2c8e8e693524afa9be5406ba4e7c785,
title = "Treatments used for obsessive-compulsive disorder-An international perspective",
abstract = "OBJECTIVE: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive-compulsive disorder (OCD).METHODS: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated.RESULTS: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD.CONCLUSIONS: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.",
author = "Vlasios Brakoulias and Vladan Starcevic and Umberto Albert and Arumugham, {Shyam Sundar} and Bailey, {Brenda E} and Amparo Belloch and Tania Borda and Liliana Dell'Osso and Elias, {Jason A} and Falkenstein, {Martha J} and Ferrao, {Ygor A} and Fontenelle, {Leonardo F} and Lena Jelinek and Leto Kalogeraki and Brian Kay and Laurito, {Luana D} and Christine Lochner and Giuseppe Maina and Donatella Marazziti and Andrew Martin and Hisato Matsunaga and Miguel, {Euripedes C} and Pedro Morgado and Irakis Mourikis and Massimo Pasquini and {Perez Rivera}, Rodrigo and Sriramya Potluri and Reddy, {Janardhan Y C} and Riemann, {Brian C} and {do Rosario}, {Maria Concei{\c c}{\~a}o} and Shavitt, {Roseli G} and Stein, {Dan J} and Kirupumani Viswasam and Zhen Wang and Fineberg, {Naomi A}",
note = "{\textcopyright} 2019 John Wiley & Sons, Ltd.",
year = "2019",
month = jan,
doi = "10.1002/hup.2686",
language = "English",
volume = "34",
pages = "e2686",
journal = "HUM PSYCHOPHARM CLIN",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Treatments used for obsessive-compulsive disorder-An international perspective

AU - Brakoulias, Vlasios

AU - Starcevic, Vladan

AU - Albert, Umberto

AU - Arumugham, Shyam Sundar

AU - Bailey, Brenda E

AU - Belloch, Amparo

AU - Borda, Tania

AU - Dell'Osso, Liliana

AU - Elias, Jason A

AU - Falkenstein, Martha J

AU - Ferrao, Ygor A

AU - Fontenelle, Leonardo F

AU - Jelinek, Lena

AU - Kalogeraki, Leto

AU - Kay, Brian

AU - Laurito, Luana D

AU - Lochner, Christine

AU - Maina, Giuseppe

AU - Marazziti, Donatella

AU - Martin, Andrew

AU - Matsunaga, Hisato

AU - Miguel, Euripedes C

AU - Morgado, Pedro

AU - Mourikis, Irakis

AU - Pasquini, Massimo

AU - Perez Rivera, Rodrigo

AU - Potluri, Sriramya

AU - Reddy, Janardhan Y C

AU - Riemann, Brian C

AU - do Rosario, Maria Conceição

AU - Shavitt, Roseli G

AU - Stein, Dan J

AU - Viswasam, Kirupumani

AU - Wang, Zhen

AU - Fineberg, Naomi A

N1 - © 2019 John Wiley & Sons, Ltd.

PY - 2019/1

Y1 - 2019/1

N2 - OBJECTIVE: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive-compulsive disorder (OCD).METHODS: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated.RESULTS: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD.CONCLUSIONS: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.

AB - OBJECTIVE: The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive-compulsive disorder (OCD).METHODS: Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated.RESULTS: The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD.CONCLUSIONS: The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.

U2 - 10.1002/hup.2686

DO - 10.1002/hup.2686

M3 - SCORING: Journal article

C2 - 30628745

VL - 34

SP - e2686

JO - HUM PSYCHOPHARM CLIN

JF - HUM PSYCHOPHARM CLIN

SN - 0885-6222

IS - 1

ER -